Literature DB >> 35965674

Improving clinical trial interpretation with ACCEPT analyses.

Michelle N Clements1, Ian R White1, Andrew J Copas1, Victoria Cornelius2, Suzie Cro2, David T Dunn2, Matteo Quartagno1, Rebecca M Turner1, Conor D Tweed1, A Sarah Walker1.   

Abstract

Entities:  

Year:  2022        PMID： 35965674      PMCID： PMC7613267          DOI： 10.1056/EVIDctw2200018

Source DB:  PubMed          Journal:  NEJM Evid        ISSN： 2766-5526


× No keyword cloud information.
  14 in total

Review 1.  Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours.

Authors:  T P Shakespeare; V J Gebski; M J Veness; J Simes
Journal:  Lancet       Date:  2001-04-28       Impact factor: 79.321

2.  Bayesian design and analysis of active control clinical trials.

Authors:  R Simon
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

3.  Assessing noninferiority in a three-arm trial using the Bayesian approach.

Authors:  Pulak Ghosh; Farouk Nathoo; Mithat Gönen; Ram C Tiwari
Journal:  Stat Med       Date:  2011-04-26       Impact factor: 2.373

4.  New Guidelines for Statistical Reporting in the Journal.

Authors:  David Harrington; Ralph B D'Agostino; Constantine Gatsonis; Joseph W Hogan; David J Hunter; Sharon-Lise T Normand; Jeffrey M Drazen; Mary Beth Hamel
Journal:  N Engl J Med       Date:  2019-07-18       Impact factor: 91.245

5.  Oral versus Intravenous Antibiotics for Bone and Joint Infection.

Authors:  Ho-Kwong Li; Ines Rombach; Rhea Zambellas; A Sarah Walker; Martin A McNally; Bridget L Atkins; Benjamin A Lipsky; Harriet C Hughes; Deepa Bose; Michelle Kümin; Claire Scarborough; Philippa C Matthews; Andrew J Brent; Jose Lomas; Roger Gundle; Mark Rogers; Adrian Taylor; Brian Angus; Ivor Byren; Anthony R Berendt; Simon Warren; Fiona E Fitzgerald; Damien J F Mack; Susan Hopkins; Jonathan Folb; Helen E Reynolds; Elinor Moore; Jocelyn Marshall; Neil Jenkins; Christopher E Moran; Andrew F Woodhouse; Samantha Stafford; R Andrew Seaton; Claire Vallance; Carolyn J Hemsley; Karen Bisnauthsing; Jonathan A T Sandoe; Ila Aggarwal; Simon C Ellis; Deborah J Bunn; Rebecca K Sutherland; Gavin Barlow; Cushla Cooper; Claudia Geue; Nicola McMeekin; Andrew H Briggs; Parham Sendi; Elham Khatamzas; Tri Wangrangsimakul; T H Nicholas Wong; Lucinda K Barrett; Abtin Alvand; C Fraser Old; Jennifer Bostock; John Paul; Graham Cooke; Guy E Thwaites; Philip Bejon; Matthew Scarborough
Journal:  N Engl J Med       Date:  2019-01-31       Impact factor: 91.245

6.  Bayesian approach to bioequivalence assessment: an example.

Authors:  H Fluehler; A P Grieve; D Mandallaz; J Mau; H A Moser
Journal:  J Pharm Sci       Date:  1983-10       Impact factor: 3.534

7.  A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.

Authors:  Andrew J Nunn; Patrick P J Phillips; Sarah K Meredith; Chen-Yuan Chiang; Francesca Conradie; Doljinsuren Dalai; Armand van Deun; Phan-Thuong Dat; Ngoc Lan; Iqbal Master; Tesfamarium Mebrahtu; Daniel Meressa; Ronelle Moodliar; Nosipho Ngubane; Karen Sanders; Stephen Bertel Squire; Gabriela Torrea; Bazarragchaa Tsogt; I D Rusen
Journal:  N Engl J Med       Date:  2019-03-13       Impact factor: 91.245

8.  Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial.

Authors:  Abbot R Laptook; Seetha Shankaran; Jon E Tyson; Breda Munoz; Edward F Bell; Ronald N Goldberg; Nehal A Parikh; Namasivayam Ambalavanan; Claudia Pedroza; Athina Pappas; Abhik Das; Aasma S Chaudhary; Richard A Ehrenkranz; Angelita M Hensman; Krisa P Van Meurs; Lina F Chalak; Amir M Khan; Shannon E G Hamrick; Gregory M Sokol; Michele C Walsh; Brenda B Poindexter; Roger G Faix; Kristi L Watterberg; Ivan D Frantz; Ronnie Guillet; Uday Devaskar; William E Truog; Valerie Y Chock; Myra H Wyckoff; Elisabeth C McGowan; David P Carlton; Heidi M Harmon; Jane E Brumbaugh; C Michael Cotten; Pablo J Sánchez; Anna Maria Hibbs; Rosemary D Higgins
Journal:  JAMA       Date:  2017-10-24       Impact factor: 56.272

9.  Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

Authors:  M A Boyd; N Kumarasamy; C L Moore; C Nwizu; M H Losso; L Mohapi; A Martin; S Kerr; A H Sohn; H Teppler; O Van de Steen; J-M Molina; S Emery; D A Cooper
Journal:  Lancet       Date:  2013-06-15       Impact factor: 79.321

10.  Perioperative haemodynamic therapy for major gastrointestinal surgery: the effect of a Bayesian approach to interpreting the findings of a randomised controlled trial.

Authors:  Elizabeth G Ryan; Ewen M Harrison; Rupert M Pearse; Simon Gates
Journal:  BMJ Open       Date:  2019-03-07       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.